Failed drug trials
In the news: Alzheimer’s drug trial set back
We’re disappointed that Biogen AND Eisai have stopped two phase III trials of Alzheimer’s drug aducanumab. But we’re encouraged by the growing number of new avenues being explored by researchers across the world. Their work has never been more important.
Solanezumab: Is the first disease-modifying treatment for Alzheimer’s on the horizon?
We’re hearing in the news that a new treatment designed to slow Alzheimer’s has shown benefit in one of the final stages of testing in people. So what’s going on?
Dementia Forum 2015 report: a global call to action
The report shines a necessary spotlight on some of the challenges facing dementia research today.
The Global Clinical Trials Fund: drugs and dummies
One year since the G8 Dementia Summit, new investment and exciting initiatives are bringing us closer to a treatment for dementia.
The failure rate of clinical trials for Alzheimer’s – why we need to raise our game
We need to learn from recent failings in clinical trials and inform research feeding back into the early drug development pipeline.
When will there be new Alzheimer’s treatments?
We look at the most promising developments in the treatments of Alzheimer’s disease.
What to expect from the next five years of dementia research
Alzheimer’s Research UK’s Director of Research Dr Eric Karran spoke recently about his hopes for the development of new Alzheimer’s treatments and dementia research.
When is a failed clinical trial not a failure?
The latest results from the Elan dementia trials have proved one of the more interesting dementia research stories of the summer.
Right drug, right patient, right time
This month we’ll be at the political party conferences urging all parties to continue to back dementia research. With no new drugs since 2003, and those in existence only showing modest efficacy, we desperately need new treatments that can delay the onset, slow the progression and manage the symptoms of dementia.
